Virtual Seminar: Von Willebrand Factor Inhibition in Acute Ischemic Stroke: From Target to Trial
Shahid Nimjee, M.D., Ph.D.
Associate Professor of Neurological Surgery
Co-Director, Stroke Center
Wexner Medical Center
The Ohio State University
Virtual Timothy A. Johnson Medical Scholar Lecture: Von Willebrand Factor Inhibition in Acute Ischemic Stroke: From Target to Trial
About this Seminar
Acute ischemic stroke (AIS) is the leading cause of combined morbidity and mortality worldwide. Recombinant tissue plasminogen activator (rtPA) is the only approved pharmacological treatment for AIS but is limited to treating patients within 4.5 hours of stroke onset because of the risk of intracranial hemorrhage. Moreover, it is ineffective in treating large vessel occlusion (LVO) stroke. Endovascular mechanical thrombectomy (MT) effectively recanalizes LVO stroke but it is limited to highly-specialized hospitals, leaving the vast majority without timely acute treatment. Dr. Nimjee hypothesizes that targeted von Willebrand Factor (VWF) inhibition by BB-031 will recanalize arterial thrombosis in a canine model of LVO stroke. Utilizing a canine embolic middle cerebral artery occlusion (eMCAO) model of LVO stroke, his lab assessed BB-031 administration at 0.5mg/kg 6 hours after stroke induction on platelet activity by PFA-100, vessel recanalization by digital subtraction angiography, infarct volume and intracranial hemorrhage by MRI. BB-031 administration after 6 hours of LVO stroke resulted complete inhibition of platelet activity. Moreover, it recanalized MCAO to >TICI 2A in 62.5% and >TICI 2B in 50% of canines (n=8). Negative control group demonstrated no revascularization (n=7). Recanalization resulted in reduced infarct volume compared to negative control (p<0.05). BB-031 administration induced no intracranial hemorrhage. VWF inhibition by BB-031 completely inhibited platelet activity, and effectively recanalizes LVO when administered 6 hours after stroke onset. Recanalization resulted in reduced infarct volume, without any incidence of intracranial hemorrhage. Targeted therapy against VWF represents a robust yet safe approach to treat AIS.
Additional Details
This is a free event hosted by the Fralin Biomedical Research Institute and the Virginia Tech Carilion School of Medicine. The Timothy A. Johnson Medical Scholar Lecture Series hosts clinician scientists who are exploring frontiers of medicine. These lectures are principally intended for Virginia Tech Carilion School of Medicine students and Virginia Tech students in the Translational Biology, Medicine, and Health graduate program. Virginia Tech and Carilion Clinic faculty, staff, and students may also attend.
You May Also Be Interested In...
-
Home Item
A Novel Bispecific Antibody to Target the Brain Tumor Microenvironment , homeMay 2, 2025, 11:00 a.m. | Khuson Yun, Ph.D., Associate Professor, Department of Neurology, Houston Methodist Chair, Neurodegenerative Disease Research, Houston Methodist Research Institute, Weill Cornell Medical College | Co-Sponsored by the Fralin Biomedical Research Institute Cancer Research Center – Roanoke
-
Home Item
Transformation of Information from the External World by Cortical Circuits During Learning , homeMay 9, 2025, 11:00 a.m. | Alison Barth, Ph.D., Professor, Department of Biological Sciences, Carnegie Mellon University | Co-Sponsored by the Center for Neurobiology Research, Fralin Biomedical Research Institute
-
Home Item
The Role of Exercise in Memory Function , homeMay 23, 2025, 11:00 a.m. | Henriette van Praag, Ph.D., Associate Professor, Department of Biomedical Science, Charles E. Schmidt College of Medicine, Florida Atlantic University | Co-Sponsored by the Center for Exercise Medicine Research, Fralin Biomedical Research Institute
-
Home Item
Pathways and Regulation of Cardiac Nav1.5 Channel Trafficking in Adult Myocytes , homeMay 30, 2025, 11:00 a.m. | Gea-Ny Tseng, Ph.D., Professor, Department of Physiology and Biophysics, Virginia Commonwealth University School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Center for Vascular and Heart Research
-
Home Item
Targeting Acquired Dependencies During Tumor Evolution , homeJune 6, 2025, 11:00 a.m. | Kris Wood, Ph.D., Associate Professor, Department of Pharmacology and Cancer Biology, Duke University School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Cancer Research Center – D.C.